检验

订阅

MedSci主页 / 所有栏目 / 检验

新型DNA血液测试技术检测肺癌患者的突变

2015-04-20 佚名 生物谷

DNA血液测试肺癌
关注

近日，来自瑞士的科学家们表示，在肺癌患者机体血液中循环的癌症DNA可以为医生们提供重要的突变信息，来帮助医生在患者肿瘤组织不易靶向作用的情况下对癌症疗法进行优化；相关研究为有效利用癌症疗法来靶向作用特殊癌症的突变提供了新的思路。检测肿瘤自身的突变并不总是有可能，然而很多研究都表明，循环在患者机体血液中的肿瘤DNA或许可以提供一些重要的指示信息。这项研究中研究者旨在对比标准方法检测肿瘤和利用血液检测

近日，来自瑞士的科学家们表示，在肺癌患者机体血液中循环的癌症DNA可以为医生们提供重要的突变信息，来帮助医生在患者肿瘤组织不易靶向作用的情况下对癌症疗法进行优化；相关研究为有效利用癌症疗法来靶向作用特殊癌症的突变提供了新的思路。

检测肿瘤自身的突变并不总是有可能，然而很多研究都表明，循环在患者机体血液中的肿瘤DNA或许可以提供一些重要的指示信息。这项研究中研究者旨在对比标准方法检测肿瘤和利用血液检测EGFR突变之间的差异。Reck说道，即使肺部肿瘤不能通过支气管窥镜检查或CT引导活检法来发现，是否存在一种可用的方法可以帮助检测EGFR的突变并且可以提供开发超级疗法的思路呢？而且是否血液检测方法可以和金标准法得到同样的结果呢？

本文研究中，研究者对1162份匹配的组织和血液样本进行了检测，结果显示血液检测手段和标准的组织检测方法得到的结果有89%的一致性，而且血液检测可以鉴别出一半的EGFR突变患者，而组织检测的敏感性仅为46%。Rafael Rosell表示，对于癌症患者而言，无细胞的血液DNA检测是一种有效的工具来帮助检测肿瘤组织的遗传改变，相关的研究结果也可以帮助科学家们证实，在几乎一半的肺癌患者血液或血浆中中可以直接检测到其携带的EGFR突变。

本文研究或可帮助改进当前的技术，来进行肺癌患者的EGFR突变敏感性检测；该研究也为后期进行更为深入的研究来扩展检测突变的常规应用，比如EGFR突变可以作为治疗癌症患者的一部分。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2016-01-27 gds2009

    #肺癌患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2016-02-18 yangeasy

    #血液测试#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2015-04-21 匿名用户

    求原文链接

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2015-04-20 cspcsp

    有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2015-04-20 cspcsp

    有道理

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2015-04-20 lecoo

    学习中

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1990542, encodeId=6abb19905426e, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jan 27 15:21:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951112, encodeId=6bb41951112f5, content=<a href='/topic/show?id=580a89302c6' target=_blank style='color:#2F92EE;'>#血液测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89302, encryptionId=580a89302c6, topicName=血液测试)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Thu Feb 18 05:21:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21531, encodeId=117a2153192, content=求原文链接, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 21 08:05:00 CST 2015, time=2015-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21487, encodeId=00dd2148ebe, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21488, encodeId=b82d214885c, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Mon Apr 20 22:52:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21482, encodeId=a111214826c, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=lecoo, createdTime=Mon Apr 20 22:31:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21459, encodeId=6b2a214598d, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Apr 20 19:19:00 CST 2015, time=2015-04-20, status=1, ipAttribution=)]
    2015-04-20 hbwang006

    有道理

    0